Videos
Are Clinical Trials Safe for Multiple Myeloma? (In Less Than a Minute) If you’ve been told about a clinical trial for multiple myeloma, you may be wondering—are clinical trials safe? In less than a minute, Beth Faiman from the International Myeloma Foundation's Nurse Leadership Board explains…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the March 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Early Signs of Multiple Myeloma: Symptoms, MGUS, and When to See a Doctor If you've searched for MGUS, smoldering myeloma, or early symptoms of multiple myeloma, this video explains what you should know. The International Myeloma Foundation’s Dr. Joseph Mikhael and nurse practitioner Beth…
Videos
Download Slides
News Article
Bristol Myers Squibb’s Mezigdomide Delivers Positive Phase 3 Results, Potentially Opening the Door for More CELMoDs in Myeloma TreatmentMarch 9, 2026—According to a press release today from Bristol-Myers Squibb,"Positive interim Phase 3 results from the SUCCESSOR-2 study (…
News Article
Tec-Dara for the treatment of RRMM is the third FDA drug approval under the Commissioner's National Priority Voucher (CNPV) Pilot Program. On Thursday, March 5, the U…
IMF Person
Ed joined the IMF in 2025 as Gift Processing and Donor Data Specialist, pairing nearly two decades' experience in nonprofit data management with a background in film studies (UC Santa Cruz) and passion for recognizing the people & stories behind every record. Living with a personal & family…
Videos
ASH 2025 Myeloma Update: Bispecific Antibodies & 3-Year Remission Data One of the most talked-about studies from ASH 2025 in multiple myeloma was MajesTEC-3, showing over 80% of patients in early relapse remained in remission at three years.In this video, Dr. Joseph Mikhael explains what…
News Article
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month STUDIO CITY, CA, February 26, 2026 — Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month — an…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the February 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Is CAR T-cell Therapy Getting Safer and More Effective? What ASH 2025 Means for Myeloma PatientsCAR T-cell therapy has transformed multiple myeloma treatment and new research from ASH 2025 may make it safer, more effective, and more accessible.In this video, Dr. Joseph Mikhael, Chief Medical Office…
News Article
New drug application (NDA) for iberdomide has been accepted by the U.S. FDA On Tuesday, February 17, the U.S. Food and Drug Administration accepted the new drug application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone) as treatment…
Videos
What Is Multiple Myeloma?If you’ve just heard the words multiple myeloma, MGUS, or smoldering myeloma, this video explains everything in clear, human language. Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, describes what myeloma…
IMF Person
Stephen L. Houff, MD brings a unique combination of clinical expertise, healthcare leadership, and personal advocacy to the International Myeloma Foundation Board of Directors. A graduate of the University of Maryland School of Medicine, Dr. Houff practiced clinical medicine for…
Videos
Multiple Myeloma Q&A: CAR T-cell Therapy, Steroids, Remission vs Cure, Kidneys, Bone Health, & More In this Q&A, Dr. Joseph Mikhael (Chief Medical Officer, International Myeloma Foundation) answers real questions from people living with myeloma, their families and care partners. He…
News Article
STUDIO CITY, CA, January 29, 2026 — The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors. After going to medical school at the University of Maryland School of Medicine and doing residency at the…
News Article
On Monday, January 26, Innovent Biologics announced via press release that the U.S. Food and Drug Administration has granted fast track designation to anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 as treatment for relapsed/refractory multiple myeloma (RRMM). …
Videos
IMF's President and CEO: Heather Cooper Ortner Answers Your QuestionsHeather Cooper Ortner, President & CEO of the International Myeloma Foundation (IMF), shares her story and answers questions from the myeloma community including patients, care partners, support group leaders, nurses, and…
News Article
On Tuesday, January 27, the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of “adults with newly diagnosed multiple myeloma who are ineligible for…
Author
Heather Cooper Ortner brings deep institutional knowledge and executive leadership to her role as President & CEO of the International Myeloma Foundation. With longstanding ties to the IMF—including seven years with the organization and prior service as Executive Vice President of Development—…
Talquetamab + Teclistamab Show Promising Efficacy in Relapsed/Refractory Multiple Myeloma with EMD
Videos
The RedirecTT-1 Phase 2 trial evaluated the efficacy and safety of talquetamab, an anti-GPRC5D×CD3 therapy, combined with teclistamab, an anti-BCMA×CD3 therapy, in patients with triple-class exposed relapsed/refractory multiple myeloma and true extramedullary disease. With a median follow-up of…
News Article
On Tuesday, January 20, a draft guidance was released by the U.S.…
Videos
The Kilimanjaro Phase 1b study evaluated etentamig, a second-generation BCMA×CD3 bispecific T-cell engager with bivalent BCMA binding and low-affinity CD3 binding enabling quarterly dosing, combined with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma. Eighty-five heavily…
Videos
This CARTITUDE-4 subgroup analysis evaluated long-term progression-free survival outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with standard-risk cytogenetics among those with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy. With 33.6 months median follow…
Videos
The Phase 2 iMMagine-1 registrational trial evaluated anitocabtagene autoleucel (anito-cel), an anti-BCMA CAR-T therapy featuring a novel D-domain binder with unique attributes including small size, simple structure, and fast off-rate designed to enhance transduction efficiency and reduce tonic…
Videos
ELREXFIO® (elranatamab-bcmm) and Bispecific Antibodies for Multiple MyelomaHow Bispecific Antibodies like Elrexfio Work, What to Expect, and Why Safety Monitoring MattersBispecific antibodies are an important type of immunotherapy used in multiple myeloma care, especially for patients who have…
Author
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPOCleveland Clinic Taussig Cancer InstituteIMF Nurse Leadership Board MemberDr. Faiman has become an exemplary leader in bringing critical knowledge of cancer nursing to clinical providers -…